Dinara Makenbaeva

Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4‐year follow‐up and analysis of relative progression‐free survival from the randomized ELOQUENT‐2 trial

Meletios Α. Dimopoulos, Sagar Lonial, Keith A. Betts et al. · Cancer · 2018 · 140 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials

Steve Deitelzweig, Alpesh Amin, Yonghua Jing et al. · Journal of Medical Economics · 2012 · 89 citations · Full text

Pharmacy, Cardiology, Pharmacoeconomics +17

The Direct and Indirect Cost Burden of AcuteCoronary Syndrome

Stephen S. Johnston, Suellen M. Curkendall, Dinara Makenbaeva et al. · Journal of Occupational and Environmental Medicine · 2010 · 58 citations

Medicine, Cardiology, Internal Medicine +17

Use of Real-World Claim Databases to Assess Prevalence of Comorbid Conditions Relevant to the Treatment of Chronic Myelogenous Leukemia Based on National Comprehensive Network Treatment Guidelines

Elias Jabbour, Dinara Makenbaeva, Melissa Lingohr-Smith et al. · Clinical Lymphoma Myeloma & Leukemia · 2015 · 49 citations

Medicine, Hematology, Oncology +16

Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US

Meg Franklin, Leah Burns, Samuel Perez et al. · Current Medical Research and Opinion · 2017 · 33 citations

Medicine, Hematology, Pharmacology +10